An investigation by the FDA has been launched involving the potential link between Tumor Necrosis Factor (TNF) blockers and the development of lymphoma and other cancers in children and young adults. TNF blockers currently approved for pediatric use include Enbrel (marketed by Amgen & Wyeth), Humira (marketed by Abbott Labs) and Remicade (marketed by Centocor). The makers of these products have been asked to supply the FDA with information regarding cancer cases in children receiving the treatment.
To date approximately thirty cases of cancer have been reported during a ten year period extending through April 2008. About half the cancers were Hodgkin’s and Non-Hodgkin’s lymphomas. Some cases involving leukemia, melanoma and some solid organ malignancies were reported. A review process is in place. Once the review is complete, the agency will communicate its findings and resulting recommendations to the public. We will watch this matter closely.
Source: MedScape Medical News
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.